KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt.

Sarah S Tonkin, Jennifer M Betts, Ashley N Dowd, Martin C Mahoney, Paul M Cinciripini, Robert A Schnoll, Tony P George, Rachel F Tyndale, Larry W Hawk

Nicotine Tob Res 27(12) 2328-2332

PMID40358028
PMCIDPMC12641181
DOI10.1093/ntr/ntaf095
发表日期2025-05-13
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

INTRODUCTION: Dichotomized smoking abstinence (abstinent/smoking) is the standard outcome for clinical trials, but obscures smoking behavior change. Examining both smoking probability and smoking rate as outcomes may identify unique barriers to cessation (eg, craving, affect) among individuals who are receiving treatment but unable to quit. AIMS AND METHODS: Two-part latent growth modeling examined daily smoking probability and smoking rate during the first week of the quit attempt using self-reported cigarettes per day. Smoking trajectories and the effect of 12 weeks of varenicline (vs. placebo), craving, negative affect (NA), and positive affect (PA) on these trajectories were examined among 828 adults in a randomized smoking cessation trial (NCT01314001). RESULTS: On average, smoking probability was 46% on the target quit day and increased to 50% later into the week (ps < .01). Among participants continuing to smoke, daily smoking rates were reduced to 27% of baseline rates and remained stable throughout the week (p = .62). Varenicline use was associated with lower smoking probability (p < .001). Higher craving and NA were associated with a higher smoking probability and higher smoking rates (ps ≤ .05). Higher PA was associated with a higher smoking probability, but lower smoking rates (ps < .04). CONCLUSIONS: Modeling smoking behavior, versus dichotomized abstinence, reveals differences in predictors of treatment effects. Results suggest smoking probability increases early into the quit attempt while daily smoking rates remain stable. Varenicline increases the probability of abstinence. Smoking abstinence and lower smoking rates were both associated with lower cravings and NA. However, PA demonstrated differential relationships with abstinence and smoking rates. IMPLICATIONS: This study expands clinical outcomes beyond dichotomous smoking abstinence by conducting preliminary two-part latent growth models to evaluate treatment processes and barriers to cessation on both smoking probability and smoking rate. This approach provides a complementary understanding of treatment effects and predictors of outcomes. Results suggest time, treatment, craving, and affect may have differential relationships with smoking probability versus smoking rates which would not be captured in traditional modeling for clinical trial outcomes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Observed and model implied mean smoking probability over the first week of the quit attempt. TQD = Target quit day.
非 KM Figure
Figure 2Figure 2. Observed and model implied percent of baseline smoking rate over the first week of the quit attempt. TQD = Target quit day.
非 KM Figure